| Market Cap | 611.74M | P/E | 45.09 | EPS this Y | - | Ern Qtrly Grth | 28.50% |
| Income | 35.64M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 1.00% |
| Sales | 88.18M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -9.00% |
| Dividend | N/A | Price/Book | 4.32 | EPS next 5Y | - | 52W High Chg | -39.00% |
| Recommedations | - | Quick Ratio | 8.33 | Shares Outstanding | 50.08M | 52W Low Chg | 8.00% |
| Insider Own | 20.46% | ROA | 14.29% | Shares Float | 41.52M | Beta | 0.92 |
| Inst Own | 9.33% | ROE | 19.39% | Shares Shorted/Prior | -/- | Price | 12.18 |
| Gross Margin | 91.23% | Profit Margin | 40.41% | Avg. Volume | 443 | Target Price | - |
| Oper. Margin | 62.61% | Earnings Date | Aug 28 | Volume | 27 | Change | 0.00% |
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900 and Parvysmelanotide (VLRX001), both alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone to produce cortisol and enables the combat of stress and regulation of immune responses, maintenance of blood pressure, moderation of blood sugar, and regulation of metabolism. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.